羚锐制药
(600285)
| 流通市值：108.54亿 | | | 总市值：108.66亿 |
| 流通股本：5.66亿 | | | 总股本：5.67亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,147,977,056.01 | 1,126,074,496.05 | 3,853,391,129.7 | 3,041,361,639.17 |
| 营业收入 | 2,147,977,056.01 | 1,126,074,496.05 | 3,853,391,129.7 | 3,041,361,639.17 |
| 二、营业总成本 | 1,588,839,181.41 | 848,497,974.23 | 3,029,670,519.08 | 2,332,076,667.21 |
| 营业成本 | 453,246,595.27 | 245,621,730.85 | 769,552,146.93 | 577,299,015.5 |
| 税金及附加 | 27,173,598.26 | 13,909,677.29 | 51,726,101.5 | 40,908,722.15 |
| 销售费用 | 985,497,230.91 | 527,336,627.13 | 1,828,759,703.53 | 1,437,387,330.38 |
| 管理费用 | 77,411,555.52 | 36,249,379.91 | 215,598,513.87 | 176,993,366.27 |
| 研发费用 | 52,664,113.09 | 31,483,551.8 | 169,124,390.58 | 104,600,773.85 |
| 财务费用 | -7,153,911.64 | -6,102,992.75 | -5,090,337.33 | -5,112,540.94 |
| 其中:利息费用 | 1,263,112.15 | 763,973.76 | 3,900,518.95 | 3,260,401.6 |
| 其中:利息收入 | 8,503,019.56 | 6,978,107.61 | 9,728,108.53 | 8,592,375.19 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,447,389.13 | 834,073.38 | -7,324,507.63 | 800,729.64 |
| 加:投资收益 | 21,805,834.22 | 11,026,112.95 | 49,996,026.1 | 36,727,423.67 |
| 资产处置收益 | -15,095.13 | -3,753.24 | 6,993,442.94 | 4,739,381.35 |
| 资产减值损失(新) | -336,588.99 | -48,281.4 | -608,216.19 | -58,216.77 |
| 信用减值损失(新) | -11,843,165.51 | -8,547,079.86 | -5,331,455.25 | -9,625,302.34 |
| 其他收益 | 7,668,978.01 | 4,416,009.2 | 19,828,005.08 | 16,495,599.62 |
| 四、营业利润 | 578,865,226.33 | 285,253,602.85 | 887,273,905.67 | 758,364,587.13 |
| 加:营业外收入 | 194,400.24 | 316,089 | 1,700,000.77 | 1,415,536.05 |
| 减:营业外支出 | 1,748,626.88 | 57,774.96 | 9,508,275.16 | 2,221,330.37 |
| 五、利润总额 | 577,310,999.69 | 285,511,916.89 | 879,465,631.28 | 757,558,792.81 |
| 减:所得税费用 | 79,456,322.8 | 38,070,005.91 | 117,017,775.43 | 104,022,269.61 |
| 六、净利润 | 497,854,676.89 | 247,441,910.98 | 762,447,855.85 | 653,536,523.2 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 497,854,676.89 | 247,441,910.98 | 762,447,855.85 | 653,536,523.2 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 495,091,125.56 | 246,333,622.73 | 759,503,032.53 | 650,932,609.77 |
| 少数股东损益 | 2,763,551.33 | 1,108,288.25 | 2,944,823.32 | 2,603,913.43 |
| 扣除非经常损益后的净利润 | 464,883,778.55 | 227,551,542.24 | 711,549,474.02 | 605,225,066.74 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.87 | 0.44 | 1.34 | 1.15 |
| (二)稀释每股收益 | 0.87 | 0.43 | 1.34 | 1.15 |
| 八、其他综合收益 | -51,004,009.56 | -71,032.45 | 42,390,202.71 | 4,885,283.79 |
| 归属于母公司股东的其他综合收益 | -51,030,575.36 | -86,981.68 | 42,425,136.57 | 4,864,027.4 |
| 九、综合收益总额 | 446,850,667.33 | 247,370,878.53 | 804,838,058.56 | 658,421,806.99 |
| 归属于母公司股东的综合收益总额 | 444,060,550.2 | 246,246,641.05 | 801,928,169.1 | 655,796,637.17 |
| 归属于少数股东的综合收益总额 | 2,790,117.13 | 1,124,237.48 | 2,909,889.46 | 2,625,169.82 |
| 公告日期 | 2026-08-12 | 2026-04-28 | 2026-04-28 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |